Skip to main content
About
Home
Forum
Groups
Group details
Groups-Private
Maps
Links
FAQs
Resources
Resource items
Resource nodes
HIFI
Systems
User login
Username
*
Password
*
Create new account
Request new password
lake
What is the weather on the sun
Search form
Search
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
COVID pandemic stole nearly 17 million years of life from European adults --study
Measles cases in Europe reach highest level in quarter century
Analysis: Are we prepared for another pandemic-- Former White House COVID response coordinator
White House suddenly withdraws CDC director nomination known for anti-vax views
U.S. Eviornmental Protection Agency chief announced rollback of climate change and other regulations
Recent Comments
HHS top spokesman resigns in dispute with RFK Jr.over measles
1 week 3 days ago
The terminated grants include those countering HIV, Maleria
2 weeks 11 hours ago
HHS postpones meeting of key CDC vaccine panel
3 weeks 5 hours ago
Nonprofit group says Trump's pause will be harmful to Americans
1 month 2 weeks ago
Who's online
There are currently 0 users online.
You are here
Home
Merck's COVID treatment expected to launch in China on Friday
Primary tabs
View
(active tab)
Workflow
Wed, 2023-01-11 09:50 —
mike kraft
Merck's COVID treatment expected to launch in China on Friday
Merck & Co's COVID-19 antiviral treatment molnupiravir is expected to be launched in the Chinese market on Friday, Sinopharm's president Liu Yong was quoted as saying by state-backed media outlet Kankan News on Wednesday.
Reuters
Reuters
Country / Region Tags:
China
Global
United States
General Topic Tags:
COVID-19
Treatments
Disease
Health
Mutations
Pandemics
Public Health
Science
Problem, Solution, SitRep, or ?:
Situation Report
Groups this Group Post belongs to:
Global Health
Medical - global
China Resilience Initiative
Log in
or
register
to post comments
howdy folks
Page loaded in 0.419 seconds.
Recent Comments